Kilitch Drugs (India) Ltd
KILITCH
Company Profile
Business description
Kilitch Drugs (India) Ltd is an India-based pharmaceutical company. It is engaged in the manufacture and sales of pharmaceutical products. The company offers parenteral and nasal products, oral formulations, effervescent tablets, nutritional products, medical devices, and cosmetic and health products. Some of the products offered by the company are Roipar, Roivit, PH-7, C-Seal, SRO kit, 9-VIT, HPURE, and others. The company has one reportable segment, which is the development and operations of the Pharmaceutical business.
Contact
Waman Tukaram Patil Marg
37/39, Ujagar Industrial Estate
Deonar
MumbaiMH400 088
INDT: +91 2261214100
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 March 2026
Employees
168
Stocks News & Analysis
stocks
Strong result for ASX insurer but not the new norm
Stellar first half profits but increasing competition will lower future rate increases.
stocks
Eli Lilly earnings: Weak Orforglipron obesity data weighs down a strong quarter
With today’s share drop, we think Lilly stock looks fairly valued.
stocks
Solid 2025 for A-REIT but development activity will weigh on 2026
Positive news for income investors as yield exceeds 5%.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,108.10 | 31.50 | 0.35% |
| CAC 40 | 7,743.00 | 33.68 | 0.44% |
| DAX 40 | 24,162.86 | 29.64 | -0.12% |
| Dow JONES (US) | 44,175.61 | 206.97 | 0.47% |
| FTSE 100 | 9,095.73 | 5.04 | -0.06% |
| HKSE | 24,869.54 | 10.72 | 0.04% |
| NASDAQ | 21,450.02 | 207.32 | 0.98% |
| Nikkei 225 | 41,820.48 | 761.33 | 1.85% |
| NZX 50 Index | 12,938.70 | 94.07 | 0.73% |
| S&P 500 | 6,389.45 | 49.45 | 0.78% |
| S&P/ASX 200 | 8,837.20 | 30.10 | 0.34% |
| SSE Composite Index | 3,635.78 | 0.65 | 0.02% |